My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IQVIA Holdings, Inc. Common Stock (NY:IQV)

176.69 -4.55 (-2.51%)
Official Closing Price Updated: 7:00 PM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about IQVIA Holdings, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers. 
Via StockStory
3 Reasons IQV is Risky and 1 Stock to Buy Instead
IQVIA’s stock price has taken a beating over the past six months, shedding 22.2% of its value and falling to $190.42 per share. This may have investors wondering how to approach the situation. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Earnings Scheduled For February 6, 2025
 
Via Benzinga
Analyst Expectations For IQVIA Hldgs's Future
 
Via Benzinga
How Is The Market Feeling About IQVIA Hldgs?
 
Via Benzinga
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
IQVIA recognized as a leader in IDC MarketScape’s 2024 assessment for decentralized clinical trial technologies and consulting services
From IQVIA
Via Business Wire
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials
From IQVIA
Via Business Wire
Dan Loeb Adjusts Healthcare Holdings: Danaher Stake Trimmed As Thermo Fisher Gains Favor
Loeb's Third Point LLC restructured their portfolio in last quarter of 2024. They decreased stake in Danaher Corp. and acquired stake in Thermo Fisher. 
Via Benzinga
IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence
From IQVIA
Via Business Wire
IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025
From IQVIA
Via Business Wire
IQVIA Releases 2024 Sustainability Report
From IQVIA
Via Business Wire
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings tomorrow before the bell. Here’s what investors should know. 
Via StockStory
West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect. 
Via StockStory
IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions
IQVIA reaffirms its 2025 outlook, projecting up to $16.13 billion in revenue and EPS of $11.70-$12.10. Strong TAS growth and solid R&DS bookings fuel confidence. 
Via Benzinga
Gapping S&P500 stocks in Thursday's session
Stay updated with the S&P500 gap up and gap down stocks on Thursday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Stocks Edge Higher, Bank Giants Rally, Palantir Skyrockets: What's Driving Markets Thursday?
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged... 
Via Benzinga
Topics Stocks
Wondering what's happening in today's S&P500 pre-market session?
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
IQVIA (NYSE:IQV) Exceeds Q4 Expectations, Stock Soars
Clinical research company IQVIA (NYSE: IQV) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 2.3% year on year to $3.96 billion. On the other hand, the company’s full-year revenue... 
Via StockStory
IQVIA Reports Fourth-Quarter and Full-Year 2024 Results; Reaffirms Full-Year 2025 Guidance
From IQVIA Holdings Inc.
Via Business Wire
IQVIA (IQV) Q4 Earnings Report Preview: What To Look For
Clinical research company IQVIA (NYSE: IQV) will be announcing earnings results tomorrow before market hours. Here’s what to look for. 
Via StockStory
IQVIA named to the Fortune® World’s Most Admired Companies™ list, ranked No. 1 in its sector for fourth consecutive year
From IQVIA
Via Business Wire
IQVIA to Announce Fourth-Quarter and Full-Year 2024 Results on February 6, 2025
From IQVIA
Via Business Wire
Nvidia Eyes $1 Billion In Healthcare AI Revenue: Is This The Next Growth Frontier?
Nvidia is making an ambitious leap into leveraging AI and accelerated computing to transform healthcare solutions. 
Via Benzinga
Topics Artificial Intelligence
IQVIA and NVIDIA Collaborate to Transform Healthcare and Life Sciences Through Advanced Agentic AI Solutions
From IQVIA
Via Business Wire
Digital Health Tools are Expanding in Scope and Function to Aid Patient Diagnosis, Treatment and Monitoring, Says New Report from The IQVIA Institute
From IQVIA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.